Use of prothrombin complex concentrate in warfarin anticoagulation reversal in the emergency department: a quality improvement study of administration delays
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6963
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Use of prothrombin complex concentrate in warfarin anticoagulation reversal in the emergency department: a quality improvement study of administration delays ; volume:15 ; number:1 ; day:15 ; month:3 ; year:2015 ; pages:1-10 ; date:12.2015
BMC health services research ; 15, Heft 1 (15.3.2015), 1-10, 12.2015
- Urheber
-
Bordeleau, Simon
- Beteiligte Personen und Organisationen
-
Poitras, Julien
Marceau, Danièle
Breton, Carolle
Beaupré, Pierre
Archambault, Patrick M.
SpringerLink (Online service)
- DOI
-
10.1186/s12913-015-0775-6
- URN
-
urn:nbn:de:1111-2016110519914
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bordeleau, Simon
- Poitras, Julien
- Marceau, Danièle
- Breton, Carolle
- Beaupré, Pierre
- Archambault, Patrick M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal
Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors
Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis
Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Preparation of a Nonthrombogenic Prothrombin Complex Concentrate
The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal
Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors
Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis
Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Preparation of a Nonthrombogenic Prothrombin Complex Concentrate
The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal
Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors
Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis
Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation